Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FOXA1 knock-out via CRISPR/Cas9 altered Casp-9, Bax, CCND1, CDK4, and fibronectin expressions in LNCaP cells.

Experimental biology and medicine (Maywood, N.J.) - 1 Aug 2018

Albayrak Gulsah, Konac Ece, Ugras Dikmen Asiye, Bilen Cenk Y

Abstract excerpt

Prostate cancer is one of the most common types of cancer in men and the leading cause of death in developed countries. With the aid of molecular and genetic profiling of cancers, cancer molecular subtypes are paving the way for tailored cancer therapy. FOXA1 has been identified as one of the seven molecular subtypes of prostate cancer. FOXA1 is involved in a variety of metabolic process such as glucose...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to bcl-2-Associated X Protein
Share to Caspase 9

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclin D1

Share to Cyclin-Dependent Kinase 4

Share to Epithelial-Mesenchymal Transition

Share to Fibronectins

Share to Hepatocyte Nuclear Factor 3-alpha

Share to Protein Interaction Mapping

Source

Open in PubMed Open full text

Identifiers

PMID: 30043639
DOI: 10.1177/1535370218791797
PMCID: PMC6180407

Genes

FOXA1
CCND1
CDK4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FOXA1 knock-out via CRISPR/Cas9 altered Casp-9, Bax, CCND1, CDK4, and fibronectin expressions in LNCaP cells.PMID 30043639Read ↗

In Vivo Application of CRISPR/Cas9 Revealed Implication of Foxa1 and Foxp1 in Prostate Cancer Proliferation and Epithelial PlasticitySemantic proximity Read ↗

Targeting mRNA-coding genes in prostate cancer using CRISPR/Cas9 technology with a special focus on androgen receptor signalingSemantic proximity Read ↗

Targeting the MALAT1 gene with the CRISPR/Cas9 technique in prostate cancerSemantic proximity Read ↗

Pioneer of prostate cancer: past, present and the future of FOXA1.Semantic proximity Read ↗

CRISPR Screen Contributes to Novel Target Discovery in Prostate CancerSemantic proximity Read ↗

Investigation of the Effects of Galectin-1 on Enzalutamide Sensitivity and Cellular Functions in Prostate Cancer Cells and Its Clinical Diagnostic ValueSemantic proximity Read ↗

CRISPR/Cas9 Technology Providing a Therapeutic Landscape of Metastatic Prostate CancerSemantic proximity Read ↗

In vivo genome-wide CRISPR screening identifies CITED2 as a driver of prostate cancer bone metastasisSemantic proximity Read ↗

CDK12 regulates angiogenesis of advanced prostate cancer by IGFBP3Semantic proximity Read ↗

Integrative CRISPR-Cas9 Screening Reveals Lethal Genes Driving Metastasis and Prognosis in Prostate AdenocarcinomaSemantic proximity Read ↗

Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer.Semantic proximity Read ↗

Targeting AP-1 transcription factors by CRISPR in the prostateSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.